287 related articles for article (PubMed ID: 35863668)
1. Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy.
Liang Q; Lan Y; Li Y; Cao Y; Li J; Liu Y
Eur J Pharm Biopharm; 2022 Aug; 177():260-272. PubMed ID: 35863668
[TBL] [Abstract][Full Text] [Related]
2. Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy.
Wan Z; Sun J; Xu J; Moharil P; Chen J; Xu J; Zhu J; Li J; Huang Y; Xu P; Ma X; Xie W; Lu B; Li S
Acta Biomater; 2019 May; 90():300-313. PubMed ID: 30930305
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic efficacy and safety improvements of crizotinib prodrug micelles on breast cancer treatment.
Cao Y; Liang Q; Lan Y; Liu Y
Pharm Dev Technol; 2022 Apr; 27(4):469-478. PubMed ID: 35579888
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy.
Sun J; Liu Y; Chen Y; Zhao W; Zhai Q; Rathod S; Huang Y; Tang S; Kwon YT; Fernandez C; Venkataramanan R; Li S
J Control Release; 2017 Jul; 258():43-55. PubMed ID: 28501705
[TBL] [Abstract][Full Text] [Related]
5. Novel glucosylceramide synthase inhibitor based prodrug copolymer micelles for delivery of anticancer agents.
Xu J; Zhao W; Sun J; Huang Y; Wang P; Venkataramanan R; Yang D; Ma X; Rana A; Li S
J Control Release; 2018 Oct; 288():212-226. PubMed ID: 30223045
[TBL] [Abstract][Full Text] [Related]
6. Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier.
Sun JJ; Chen YC; Huang YX; Zhao WC; Liu YH; Venkataramanan R; Lu BF; Li S
Acta Pharmacol Sin; 2017 Jun; 38(6):823-834. PubMed ID: 28504251
[TBL] [Abstract][Full Text] [Related]
7. A prodrug micellar carrier assembled from polymers with pendant farnesyl thiosalicylic acid moieties for improved delivery of paclitaxel.
Sun J; Chen Y; Li K; Huang Y; Fu X; Zhang X; Zhao W; Wei Y; Xu L; Zhang P; Venkataramanan R; Li S
Acta Biomater; 2016 Oct; 43():282-291. PubMed ID: 27422196
[TBL] [Abstract][Full Text] [Related]
8. Tumor Microenvironment-Triggered Charge Reversal Polymetformin-Based Nanosystem Co-Delivered Doxorubicin and IL-12 Cytokine Gene for Chemo-Gene Combination Therapy on Metastatic Breast Cancer.
Sun Y; Liu L; Zhou L; Yu S; Lan Y; Liang Q; Liu J; Cao A; Liu Y
ACS Appl Mater Interfaces; 2020 Oct; 12(41):45873-45890. PubMed ID: 32924511
[TBL] [Abstract][Full Text] [Related]
9. Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs.
Xu J; Sun J; Wang P; Ma X; Li S
J Drug Target; 2018; 26(5-6):448-457. PubMed ID: 29251528
[TBL] [Abstract][Full Text] [Related]
10. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
[TBL] [Abstract][Full Text] [Related]
11. Codelivered Chemotherapeutic Doxorubicin
Lan Y; Liang Q; Sun Y; Cao A; Liu L; Yu S; Zhou L; Liu J; Zhu R; Liu Y
ACS Appl Mater Interfaces; 2020 Jul; 12(28):31904-31921. PubMed ID: 32551517
[TBL] [Abstract][Full Text] [Related]
12. Synergistic action of doxorubicin and 7-Ethyl-10-hydroxycamptothecin polyphosphorylcholine polymer prodrug.
Wu Z; Li S; Cai Y; Chen F; Chen Y; Luo X
Colloids Surf B Biointerfaces; 2020 May; 189():110741. PubMed ID: 32032928
[TBL] [Abstract][Full Text] [Related]
13. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier.
Ma W; Sun J; Xu J; Luo Z; Diao D; Zhang Z; Oberly PJ; Minnigh MB; Xie W; Poloyac SM; Huang Y; Li S
Theranostics; 2020; 10(6):2463-2478. PubMed ID: 32194813
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of 2-Deoxyglucose and a glutamine metabolism inhibitor V9302 via a prodrug micellar formulation for synergistic targeting of metabolism in cancer.
Luo Z; Xu J; Sun J; Huang H; Zhang Z; Ma W; Wan Z; Liu Y; Pardeshi A; Li S
Acta Biomater; 2020 Mar; 105():239-252. PubMed ID: 31958597
[TBL] [Abstract][Full Text] [Related]
15. Self-Assembled Immunostimulatory Tetrahedral Framework Nucleic Acid Vehicles for Tumor Chemo-immunotherapy.
Liu M; Hao L; Zhao D; Li J; Lin Y
ACS Appl Mater Interfaces; 2022 Aug; 14(34):38506-38514. PubMed ID: 35973112
[TBL] [Abstract][Full Text] [Related]
16. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
[TBL] [Abstract][Full Text] [Related]
17. Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy.
Wei X; Liu L; Li X; Wang Y; Guo X; Zhao J; Zhou S
J Control Release; 2019 Nov; 313():42-53. PubMed ID: 31629039
[TBL] [Abstract][Full Text] [Related]
18. Transformable prodrug nanoplatform
Yang W; Yi J; Zhu R; Guo Y; Zhang K; Cao Y; Li X; Zhang J; Zhang Z; Li Y; Chen X
Theranostics; 2023; 13(6):1906-1920. PubMed ID: 37064869
[No Abstract] [Full Text] [Related]
19. Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.
Kim J; Shim MK; Moon Y; Kim J; Cho H; Yun WS; Shim N; Seong JK; Lee Y; Lim DK; Kim K
J Nanobiotechnology; 2024 Mar; 22(1):109. PubMed ID: 38481326
[TBL] [Abstract][Full Text] [Related]
20. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer.
Zang X; Song J; Yi X; Piyu J
J Mater Chem B; 2022 Mar; 10(12):2019-2027. PubMed ID: 35254372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]